The Technical Analyst
Recro Pharma Inc [REPH]
Exchange: NASDAQ Capital Market Sector: Healthcare Industry: Drug Manufacturers—Specialty & Generic
Recro Pharma Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
-0.48% $2.09
Last updated: 16 May 2022 @ 12:29 pm
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 123.23 mill |
| EPS: | -0.260 |
| P/E: | 0.000 |
| Earnings Date: | May 04, 2022 |
| SharesOutstanding: | 58.96 mill |
| Avg Daily Volume: | 0.128 mill |
| RATING 2022-05-13 |
|---|
| A- |
| Buy |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$2.58 (23.47%) $0.490 |
| Date: 2022-05-16 |
| True Range Average |
|---|
|
+/- $0.128 ( +/- 13.85%) Range: 0.796 - 1.052 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-04-30 | Lake Ryan David | Sell | 1 198 | Common Stock |
| 2022-04-20 | Awm Investment Company, Inc. | Buy | 12 100 | Common Stock |
| 2022-04-19 | Awm Investment Company, Inc. | Buy | 12 100 | Common Stock |
| 2022-04-18 | Awm Investment Company, Inc. | Buy | 15 000 | Common Stock |
| 2022-04-18 | Awm Investment Company, Inc. | Buy | 600 | Common Stock |
| INSIDER POWER |
|---|
| 48.78 |
| Last 100 transactions |
| Buy: 2 853 124 | Sell: 1 017 405 |
Forecast:
14:09 - $2.09
Live Trading Signals (every 1 min)
Forecast
1: 12:39 - $2.09
Forecast 2: 13:29 - $2.09
Forecast 3: 14:09 - $2.09
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $2.09 (-0.48% ) |
| Volume | 0.138 mill |
| Avg. Vol. | 0.128 mill |
| % of Avg. Vol | 107.04 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For REPH
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since 31-12-69
| Date | Signal | @ | Closed | % | Apr 20 - 14:59 | sell | $2.09 | N/A | Active |
|---|
REPH
Recro Pharma, Inc. a contract development and manufacturing organization, engages in the development, manufacturing, and packaging of oral solid dose drug products to pharmaceutical market in the United States and internationally. The company was formerly known as Recro Pharma I, Inc. and changed its name to Recro Pharma, Inc. in August 2008. Recro Pharma, Inc. was founded in 2007 and is based in Malvern, Pennsylvania.
Latest Press Releases
2022-03-21 07:00:00 - Press Release
Recro Announces Name Change To Societal Cdmo To Reflect Corporate Expansion And Transformation
With expanded industry expertise, enhanced service offerings and bi-coastal operations, company now optimally positioned to support customers' goal of delivering impactful medicines to society
2022-03-01 16:05:00 - Press Release
Recro Reports Fourth Quarter And Year End 2021 Financial Results
Recorded q4 revenue of $22.3 million; full year revenue of $75.4 million
2022-01-26 07:00:00 - Press Release
Recro Wins $1.5 Million Formulation Development And Cgmp Manufacturing Contract To Support Clinical Development Of Topical Treatment For Skin Cancer Prevention
San diego, and gainesville, ga., jan. 26, 2022 (globe newswire) -- recro pharma, inc. (“recro”; nasd: reph), a contract development and manufacturing organization (cdmo) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has been awarded a new formulation development and cgmp manufacturing contract from a key department of the united states government. the contract focuses on supporting clinical development of a topical dermal treatment for the prevention of skin cancer.
2022-01-19 07:00:00 - Press Release
Recro Appoints Eduardo Uribe As Head Of Quality For Recro San Diego
Latest appointment continues build-out of leadership team for san diego operations latest appointment continues build-out of leadership team for san diego operations
2021-10-27 07:00:00 - Press Release
Recro Enters Into Master Commercial Supply And Services Agreement With Otsuka
Agreement establishes recro as commercial supplier for otsuka
Latest News
2022-03-01 19:33:06 - Seeking Alpha
Recro Pharma, Inc. (REPH) CEO David Enloe on Q4 2021 Results - Earnings Call Transcript
2022-02-22 16:05:00 - GlobeNewsWire
Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022
Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. Eastern
2022-01-03 07:00:00 - GlobeNewsWire
Recro to Present at H.C. Wainwright BioConnect 2022 Conference
SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that its chief executive officer, David Enloe, will deliver a corporate presentation as part of the H.C. Wainwright BioConnect 2022 Conference. The conference, which will take place January 10-13, 2022, is being conducted with a virtual format.
2021-12-08 10:36:22 - Zacks Investment Research
Do Options Traders Know Something About Recro Pharma (REPH) Stock We Don't?
Investors need to pay close attention to Recro Pharma (REPH) stock based on the movements in the options market lately.
2021-11-10 02:20:30 - Seeking Alpha
Recro Pharma, Inc. (REPH) CEO David Enloe on Q3 2021 Results - Earnings Call Transcript
2021-10-20 15:07:17 - Benzinga
Recro Secures Manufacturing Contract From NIH For Nasal Spray Analgesic
Recro Pharma Inc (NASDAQ: REPH) has been awarded a new development and manufacturing contract by the National Center for Advancing Translational Sciences at the National Institutes of Health (NIH). The new contract is an individual $1.87 million task order that falls under an existing NIH parent contract previously awarded to IriSys, the San Diego-based CDMO that Recro recently acquired.
2021-10-06 07:00:00 - GlobeNewsWire
Recro Reports Inducement Grants For New Staff
Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego Highlights Appointment of New Vice President and Site Head of Operations for Recro San Diego
2021-10-01 10:09:33 - Zacks Investment Research
Recro Pharma (REPH) Sees Hammer Chart Pattern: Time to Buy?
Recro Pharma (REPH) has been struggling lately, but the selling pressure may be coming to an end soon.
2021-09-16 13:44:06 - Zacks Investment Research
Recro Pharma (REPH) Moves to Buy: Rationale Behind the Upgrade
Recro Pharma (REPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2021-08-17 07:00:00 - GlobeNewsWire
Recro to Host Webcast to Discuss Acquisition of San Diego-Based IRISYS
Acquisition Expands Recro's Global Customer Base and Service Offerings, Creates Bi-Coastal CDMO, Diversifies Pipeline and Revenue Sources, and Provides Additional Pathway for Continued Growth